DEF 14A: The Joint Corp. Aims for Growth: Proxy Statement Reveals Strategic Plans and Executive Compensation

The Joint Corp.'s proxy statement outlines the company's strategic initiatives to become a world-class franchisor, improve profitability, and drive growth, while also detailing executive compensation and corporate governance matters.

Summary

• The Joint Corp. is focused on becoming a world-class, pure-play franchisor.
• The company's strategic priorities include building people capability, excelling in patient experience, turbocharging sales and profits, reigniting clinic network growth, and innovating and broadening relevance.
• The Joint 2.0 phase will focus on strengthening the core, reigniting growth, and improving clinic and company-level profitability through refranchising and dynamic revenue management.
• The Joint 3.0 phase will explore new revenue streams through B2B business, tech differentiation, dense urban markets, new clinical services, and retail products.
• In 2024, The Joint had 14.7 million patient visits, 1.9 million unique patients, and 957,000 new patients.
• Revenue from continuing operations increased by 10% to $51.9 million, and system-wide sales grew by 9% to $530.3 million.
• The company reported a net loss from continuing operations of $1.5 million and adjusted EBITDA of $2.7 million.
• The company opened 32 new clinics, bringing the total to 967.
• The company sold 57 franchise licenses.
• The company generated $9.4 million of cash from operations.
• The annual meeting of stockholders will be held on May 21, 2025, to vote on the election of directors, executive compensation, and the ratification of the independent public accounting firm.
• Sanjiv Razdan was appointed as President and Chief Executive Officer effective October 14, 2024, with a base salary of $550,000 and eligibility for bonuses and stock awards.
• Peter D. Holt, the former President and Chief Executive Officer, resigned effective October 10, 2024, and will receive severance payments.

Sentiment

Score: 6

Explanation: The document presents a mixed sentiment. While there are positive aspects such as revenue growth and strategic plans, the net loss and decreased EBITDA temper the overall outlook. The change in CEO also introduces uncertainty.

Positives

• The Joint Corp. is the clear category leader with over 960 clinics, larger than its next 10 competitors combined.
• The company has a recurring revenue model with 85% of revenue from memberships.
• The Joint has low initial costs for clinic buildouts compared to other health and wellness concepts.
• The company has a new detailed strategic plan to strengthen its core and reignite growth.
• The company's business model has shown resiliency and validation of future opportunities and growth.
• The company generated $9.4 million of cash from operations.

Negatives

• The company reported a net loss from continuing operations of $1.5 million in 2024.
• Adjusted EBITDA from continuing operations decreased to $2.7 million in 2024, compared to $4.5 million in 2023.

Risks

• The company's success depends on the successful execution of its strategic plan.
• The company faces competition from other chiropractic care providers and health and wellness concepts.
• The company's financial performance is subject to economic conditions and consumer spending patterns.
• The company's ability to attract and retain franchisees is critical to its growth.

Future Outlook

The Joint Corp. aims to strengthen its core, reignite growth, and improve clinic and company-level profitability through refranchising, dynamic revenue management, and exploring new revenue streams.

Management Comments

• Sanjiv Razdan, President and CEO: 'My goal is to activate our talented leadership team to leverage our advantages to become a world class, pure play franchisor.'
• Sanjiv Razdan, President and CEO: 'We are implementing initiatives to improve our clinic economics and company profitability, increase clinic count, and create stockholder value.'

Industry Context

The Joint Corp. operates in the chiropractic care industry, which is estimated to have $20.6 billion in annual spending. The company aims to capture a larger share of this market through its franchise model and strategic initiatives.

Comparison to Industry Standards

• The Joint Corp. has a 14-year CAGR of 54%, significantly higher than the industry's 5-year CAGR of 5.1% according to the June 2023 Kentley Insights Chiropractic Care Market Research Report.
• The Joint Corp. has over 960 clinics, making it larger than its next 10 competitors combined, indicating a leading position in the chiropractic franchise market.
• The Joint Corp.'s asset-light, recurring revenue model is attractive to franchisees, similar to other successful franchise models in the health and wellness industry, such as Anytime Fitness or Planet Fitness.
• The Joint Corp.'s focus on membership-based services aligns with industry trends towards recurring revenue models, as seen in companies like Massage Envy.

Management Changes

Related Party Transactions

• Mr. Jefferson Gramm, the Managing Partner of Bandera Partners LLC, who is a beneficial holder of more than 5% of our outstanding common stock (approximately 26% as of December 31, 2024), was appointed to the Board of Directors effective as of January 2, 2024.
• In December 2020, we sold two franchise licenses at $39,900 and $29,900 each (which reflects the $10,000 multi-unit discount for the second license per the Franchise Disclosure Document) to Mr. Marshall Gramm, who is a family member of Mr. Jefferson Gramm.
• In April 2020 and 2021, we sold two franchise licenses at $39,900 and $29,900, respectively (which reflects the $10,000 multi-unit discount for the second license per the Franchise Disclosure Document), to a franchisee of which Mr. Jefferson Gramm is a 50% co-partner in the business.
• In the fourth quarter of 2024, Mr. Jefferson Gramm divested of his interest in the clinics to which he is a 50% co-partner in the business.
• In October 2020, Mr. Gramm loaned approximately $370,000 to an unaffiliated franchisee that owns and operates one franchise clinic.
• On December 19, 2024, Bandera entered into the Amended Nomination and Standstill Agreement with us, which amends and restates in its entirety the Nomination and Standstill Agreement, dated as of November 6, 2023, by and among Bandera and us.

Stakeholder Impact

• Stockholders: The company aims to create stockholder value through improved clinic economics, increased clinic count, and potential stock repurchase programs.
• Franchisees: The company plans to turbocharge sales and profits for franchisees by bolstering its foundation and refranchising.
• Patients: The company places patients at the heart of everything it does, aiming to improve the quality of life through routine and affordable chiropractic care.
• Employees: The company plans to build its people capability and culture to support its clinics, nurture talent, strengthen engagement, and attract and retain the best Doctors of Chiropractic.

Next Steps

• The company will continue to implement its strategic plan to become a world-class franchisor.
• The company will evaluate measures to improve profitability, such as acquiring regional developer territories or implementing a stock repurchase program.
• The company will focus on growing net new clinic openings, system-wide sales, comp sales, and Adjusted EBITDA.

Key Dates

Keywords

franchisor, chiropractic, clinics, franchise, growth, EBITDA, revenue, patients, sales, The Joint Corp